Sukrut Somani

List of Publications by Year
in descending order

22 papers	660 citations	567281 15 h-index	677142 22 g-index
22 all docs	22 docs citations	22 times ranked	1141 citing authors

#	Article	IF	Citations
1	Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells. Therapeutic Delivery, 2013, 4, 629-640.	2.2	80
2	Transferrin-bearing polypropylenimine dendrimer for targeted gene delivery to the brain. Journal of Controlled Release, 2014, 188, 78-86.	9.9	75
3	PEGylation of polypropylenimine dendrimers: effects on cytotoxicity, DNA condensation, gene delivery and expression in cancer cells. Scientific Reports, 2018, 8, 9410.	3.3	57
4	Applications of dendrimers for brain delivery and cancer therapy. Nanomedicine, 2014, 9, 2403-2414.	3.3	55
5	Camptothecin-based dendrimersomes for gene delivery and redox-responsive drug delivery to cancer cells. Nanoscale, 2019, 11, 20058-20071.	5.6	51
6	Enhanced gene expression in the brain following intravenous administration of lactoferrin-bearing polypropylenimine dendriplex. Journal of Controlled Release, 2015, 217, 235-242.	9.9	39
7	Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1445-1454.	3.3	36
8	Redox-sensitive, cholesterol-bearing PEGylated poly(propylene imine)-based dendrimersomes for drug and gene delivery to cancer cells. Nanoscale, 2018, 10, 22830-22847.	5.6	35
9	Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment. British Journal of Cancer, 2020, 122, 517-527.	6.4	33
10	Regression of prostate tumors after intravenous administration of lactoferrin-bearing polypropylenimine dendriplexes encoding TNF-Î±, TRAIL, and interleukin-12. Drug Delivery, 2018, 25, 679-689.	5.7	31
11	Targeted nonviral gene therapy in prostate cancer. International Journal of Nanomedicine, 2018, Volume 13, 5753-5767.	6.7	29
12	Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E Î±-tocotrienol. Journal of Controlled Release, 2017, 246, 79-87.	9.9	27
13	Transferrinâ€bearing liposomes entrapping plumbagin for targeted cancer therapy. Journal of Interdisciplinary Nanomedicine, 2019, 4, 54-71.	3.6	26
14	Proof of concept studies for siRNA delivery by nonionic surfactant vesicles: <i>in vitro</i> and <i>in vivo</i> evaluation of protein knockdown. Journal of Liposome Research, 2019, 29, 229-238.	3.3	16
15	Regression of Melanoma Following Intravenous Injection of Plumbagin Entrapped in Transferrin-Conjugated, Lipidâ€"Polymer Hybrid Nanoparticles. International Journal of Nanomedicine, 2021, Volume 16, 2615-2631.	6.7	15
16	Octadecyl chain-bearing PEGylated poly(propyleneimine)-based dendrimersomes: physicochemical studies, redox-responsiveness, DNA condensation, cytotoxicity and gene delivery to cancer cells. Biomaterials Science, 2021, 9, 1431-1448.	5.4	13
17	Lactoferrin-Bearing Gold Nanocages for Gene Delivery in Prostate Cancer Cells in vitro. International Journal of Nanomedicine, 2021, Volume 16, 4391-4407.	6.7	11
18	Limited Impact of the Protein Corona on the Cellular Uptake of PEGylated Zein Micelles by Melanoma Cancer Cells. Pharmaceutics, 2022, 14, 439.	4.5	9

#	Article	IF	Citations
19	Lactoferrin- and Dendrimer-Bearing Gold Nanocages for Stimulus-Free DNA Delivery to Prostate Cancer Cells. International Journal of Nanomedicine, 2022, Volume 17, 1409-1421.	6.7	9
20	Anti-Tumor Activity of Intravenously Administered Plumbagin Entrapped in Targeted Nanoparticles. Journal of Biomedical Nanotechnology, 2020, 16, 85-100.	1.1	6
21	Transferrin-bearing dendrimers for cancer therapy: an update. Nanomedicine, 2015, 10, 2125-2127.	3.3	5
22	Development of transferrin-bearing vesicles encapsulating aspirin for cancer therapy. Journal of Liposome Research, 2020, 30, 174-181.	3.3	2